Cargando…
New Data for Nebivolol after In Silico PK Study: Focus on Young Patients and Dosage Regimen
Nebivolol (NEB) is a highly selective β1 receptor antagonist with a distinct pharmacological profile. This drug is approved for the treatment of hypertension in the US, and hypertension and heart failure in Europe. Here, we review observations based on age dependence and explore new drug regimens wi...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9502491/ https://www.ncbi.nlm.nih.gov/pubmed/36145659 http://dx.doi.org/10.3390/pharmaceutics14091911 |